Envestnet Asset Management Inc. Acquires 5,794 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Envestnet Asset Management Inc. lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 10.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 63,483 shares of the biopharmaceutical company’s stock after purchasing an additional 5,794 shares during the period. Envestnet Asset Management Inc. owned 0.06% of Regeneron Pharmaceuticals worth $55,757,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Eudaimonia Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.2% in the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after acquiring an additional 11 shares during the last quarter. Drive Wealth Management LLC raised its holdings in Regeneron Pharmaceuticals by 4.0% in the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 12 shares during the period. MCF Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. LCM Capital Management Inc grew its holdings in shares of Regeneron Pharmaceuticals by 2.5% in the 4th quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock valued at $427,000 after buying an additional 12 shares during the period. Finally, TrinityPoint Wealth LLC increased its position in shares of Regeneron Pharmaceuticals by 4.8% in the 4th quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 12 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $1,001.73 on Tuesday. The firm has a market cap of $110.38 billion, a P/E ratio of 29.59, a price-to-earnings-growth ratio of 2.07 and a beta of 0.13. The business’s 50 day moving average is $949.97 and its 200-day moving average is $930.22. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $1,016.00.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 787 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total value of $798,820.74. Following the completion of the sale, the chief executive officer now owns 64,198 shares in the company, valued at approximately $65,162,253.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Leonard S. Schleifer sold 787 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total value of $798,820.74. Following the completion of the transaction, the chief executive officer now directly owns 64,198 shares of the company’s stock, valued at approximately $65,162,253.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,399 shares of company stock worth $55,145,791. Corporate insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. Bank of America raised their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Truist Financial reiterated a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Finally, TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $989.86.

Check Out Our Latest Analysis on REGN

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.